Ferrari Anna, Savino Gustavo, Gallesi Daniela, Pinetti Diego, Bertolini Alfio, Sances Grazia, Coccia Ciro Pio Rosario, Pasciullo Gabriella, Leone Sheila, Loi Marianna, Sternieri Emilio
Division of Toxicology and Clinical Pharmacology, Headache Centre, University Centre for Adaptive Disorders and Headache, University of Modena and Reggio Emilia, Largo del pozzo, 71, 41100 Modena, Italy.
Pharmacol Res. 2006 Aug;54(2):142-9. doi: 10.1016/j.phrs.2006.03.022. Epub 2006 Apr 7.
The combination of indomethacin, prochlorperazine and caffeine (IPC) is one of the most utilized formulations for the treatment of migraine attacks in Italy. Several patients suffering from chronic headache overuse this symptomatic medication in the attempt to control their headache.
To verify whether overuse of IPC combination by chronic headache patients is associated with modified disposition of its components.
We studied indomethacin, prochlorperazine, and caffeine disposition in 34 female subjects suffering from primary headaches, subdivided into four groups: eight migraine patients occasionally using IPC combination suppositories-group 1; nine patients with chronic headache and probable medication-overuse headache, daily taking one or more suppositories of the IPC combination-group 2; 11 migraine patients occasionally using "mild" suppositories of the IPC combination-group 3; six migraine patients occasionally taking tablets of the IPC combination-group 4. The IPC combination habitually used was administered to each patient. Blood samples were taken at baseline and at fixed intervals up to 6h after administration. Plasma levels of indomethacin and prochlorperazine were assayed by high-pressure liquid chromatographic (HPLC) method; caffeine levels were assayed by enzyme multiplied immunoassay test (EMIT). Pharmacokinetic parameters were calculated by means of a computer software (P K Solutions 2.0. Summit Research Services, Montrose, CO, USA).
Half-life of indomethacin was longer, and clearance lower, in group 2 than in the other groups; AUC of indomethacin in group 2 was twice that in group 1 (P<0.05, Newman-Keuls' test). Peak concentrations and AUC(0-->infinity) of caffeine were significantly higher in group 2 than in the other groups (P<0.05, Newman-Keuls' test). We could not define prochlorperazine disposition because it was not detectable in the majority of blood samples.
Overuse of IPC combination in chronic headache patients is associated with increased plasma levels of indomethacin and caffeine, and with delayed elimination of indomethacin; the high and sustained concentrations of these drugs may cause rebound headache, organ damages, and perpetuate medication-overuse headache.
在意大利,吲哚美辛、丙氯拉嗪和咖啡因(IPC)联合制剂是治疗偏头痛发作最常用的配方之一。一些慢性头痛患者过度使用这种对症药物来试图控制头痛。
验证慢性头痛患者过度使用IPC联合制剂是否与其成分的代谢改变有关。
我们研究了34名原发性头痛女性受试者体内吲哚美辛、丙氯拉嗪和咖啡因的代谢情况,这些受试者被分为四组:8名偶尔使用IPC联合栓剂的偏头痛患者——第1组;9名患有慢性头痛且可能为药物过度使用性头痛的患者,每天服用一个或多个IPC联合栓剂——第2组;11名偶尔使用IPC联合“温和”栓剂的偏头痛患者——第3组;6名偶尔服用IPC联合片剂的偏头痛患者——第4组。将习惯性使用的IPC联合制剂给予每位患者。在给药前及给药后长达6小时的固定时间间隔采集血样。通过高压液相色谱(HPLC)法测定血浆中吲哚美辛和丙氯拉嗪的水平;通过酶放大免疫分析测试(EMIT)测定咖啡因水平。借助计算机软件(PK Solutions 2.0. Summit Research Services,美国科罗拉多州蒙特罗斯)计算药代动力学参数。
第2组中吲哚美辛的半衰期较长,清除率较低,与其他组相比;第2组中吲哚美辛的AUC是第1组的两倍(P<0.05,Newman-Keuls检验)。第2组中咖啡因的峰值浓度和AUC(0→∞)显著高于其他组(P<0.05,Newman-Keuls检验)。我们无法确定丙氯拉嗪的代谢情况,因为在大多数血样中无法检测到它。
慢性头痛患者过度使用IPC联合制剂与血浆中吲哚美辛和咖啡因水平升高以及吲哚美辛消除延迟有关;这些药物的高浓度和持续浓度可能导致反弹性头痛、器官损害,并使药物过度使用性头痛持续存在。